He holds a Ph.D. in nanomedicine and has expertise in nano-drug delivery, gene therapy, and five years of experience in executive management.

In his role as CEO, Alhasan develops strategic and business plans for global therapy translation and trains talents in deep tech, nanotech, and gene editing tech.

He co-developed deep tech for biotech discovery using large language models and co-invented NanoPalm's biorobots for gene editing primer delivery.

Alhasan also discovered four nanomedicines for genetic diseases and is an associate professor at King Abdulaziz City for Science and Technology and an adjunct professor at Alfaisal University, fostering collaboration agreements between the two institutions.

Dr. Alhasan is an associate professor and the principal researcher for nanomedicine and the fourth industrial revolution.

He also teaches nanomedicine and mentors students as an adjunct professor.

Previously, he held executive leadership roles at KACST, including deputy of the Joint Centers of Excellence Program, deputy of the Life Science and Environment Research Institute, director of the Center of Excellence for Biomedicine, and director of Strategic Initiatives.

Dr. Alhasan was a post-doctoral scholar at the University of California and earned his Ph.D. from Northwestern University in 2013.

Alhasan earned his bachelor's degree in medical technology from King Abdulaziz University in 2001 and his master's degree in biotechnology from Northwestern University in 2008.

Throughout his career, he received several notable awards including the Outstanding Researcher Award from the International Institute for Nanotechnology in 2012, the Outstanding Investigator Award from KACST in 2018, and the Leader of the Year award from the Ministry of Communication and Information Technology in 2024.